Growth hormone and cardiovascular risk markers

Growth Hormone and IGF Research

Volumn 13, Issue SUPPL. A, 2003, Pages

  Klibanski, Anne ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Androgen deficiency; C reactive protein; Cardiovascular risk markers; Growth hormone deficiency; Hypopituitarism; Stroke

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOCORTICOID; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 6; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEGVISOMANT; PRAVASTATIN; SERUM AMYLOID A;

ACROMEGALY; ANTHROPOMETRY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; ECHOGRAPHY; ENDOTHELIUM LESION; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; IRRADIATION; MORTALITY; OBESITY; ONSET AGE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY;

EID: 0141742723     PISSN: 10966374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-6374(03)00065-0     Document Type: Article

References (30)

1. T. Rosen, B.A. Bengtsson, Premature mortality due to cardiovascular disease in hypopituitarism, Lancet 336 (1990) 285-288.
2. B. Bulow, L. Hagmar, Z. Mikoczy, C.H. Nordstrom, E.M. Erfurth, Increased cerebrovascular mortality in patients with hypopituitarism, Clin. Endocrinol. (Oxf.) 46 (1997) 75-81.
3. M. Pfeifer, R. Verhovec, B. Zizek, J. Prezelj, P. Poredos, R.N. Clayton, Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults, J. Clin. Endocrinol. Metab. 84 (1999) 453-457.
4. L.M. Evans, J.S. Davies, J. Goodfellow, J.A. Rees, M.F. Scanlon, Endothelial dysfunction in hypopituitary adults with growth hormone deficiency, Clin. Endocrinol. (Oxf.) 50 (1999) 457-464.
5. B. Capaldo, L. Patti, U. Oliviero, S. Longobardi, F. Pardo, F. Vitale, S. Fazio, F. Di Rella, B. Biondi, G. Lombardi, L. Saccà, Increased arterial intima-media thickness in childhood-onset growth hormone deficiency, J. Clin. Endocrinol. Metab. 82 (1997) 1378-1381.
6. V. Markussias, S.A. Beshyah, C. Fisher, P. Sharp, A.N. Nicolaides, D.G. Johnston, Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults, Lancet 340 (1992) 1188-1192.
7. E.M. Erfurth, B. Bulow, G. Svahn-Tapper, B. Norrving, K. Odh, Z. Mikoczy, J. Bjork, L. Hagmar, Risk factors for cerebrovascular death in patients operated and irradiated for pituitary tumors, J. Clin. Endocrinol. Metab. 87 (2002) 4892-4899.
8. R. Ross, Atherosclerosis - an inflammatory disease, N. Engl. J. Med. 340 (1999) 115-126.
9. P. Libby, P.M. Ridker, Novel inflammatory markers of coronary risk: theory versus practice, Circulation 100 (1999) 1148-1150.
10. P.M. Ridker, M. Cushman, M.J. Stampfer, R.P. Tracy, C.H. Hennekens, Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men, N. Engl. J. Med. 336 (1997) 973-979.
11. P.M. Ridker, J.E. Buring, J. Shih, M. Matias, C.H. Hennekens, Prospective study of C-reactive protein and the risk of cardiovascular disease in apparently healthy men, N. Engl. J. Med. 98 (1998) 731-733.
12. G. Sesmilo, B.M.K. Biller, J. Llevadot, D. Hayden, G. Hanson, N. Rifai, A. Klibanski, Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial, Ann. Intern. Med. 133 (2000) 111-122.
13. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, E. Braunwald, Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators, Circulation 100 (1999) 230-235.
14. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis, E. Braunwald, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. The Cholesterol and Recurrent Events (CARE) Investigators, Circulation 335 (1999) 1001-1009.
15. G.N. Welch, J. Loscalzo, Homocysteine and atherothrombosis, N. Engl. J. Med. 338 (1998) 1042-1050.
16. C.D. Stehouwer, M.P. Weijenberg, M. van den Berg, C. Jakobs, E.J. Feskens, D. Kromhout, Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up, Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1895-1901.
17. N.J. Wald, H.C. Watt, M.R. Law, D.G. Weir, J. McPartlin, J.M. Scott, Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention, Arch. Intern. Med. 158 (1998) 862-867.
18. D.G. Hackam, J.C. Peterson, J.D. Spence, What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homecyst(e)ine levels above and below 14μmol/l, Am. J. Hypertens. 13 (2000) 105-110.
19. J.O. Jorgensen, J. Moller, T. Laursen, H. Orskov, J.S. Christiansen, J. Weeke, Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults, Clin. Endocrinol. (Oxf.) 41 (1994) 609-614.
20. J.W. Tomlinson, N. Holden, R.K. Hills, K. Wheatley, R.N. Clayton, A.S. Bates, M.C. Sheppard, P.M. Stewart, West Midlands Prospective Hypopituitary Group, Association between premature mortality and hypopituitarism. Lancet 357 (2001) 425-431.
21. P.M. Ridker, C.H. Hennekens, J.E. Buring, N. Rifai, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N. Engl. J. Med. 342 (2000) 836-843.
22. V. Mohamed-Ali, S. Goodrick, A. Rawesh, D.R. Katz, J.M. Miles, J.S. Yudkin, S. Klein, S.W. Coppack, Subcutaneous adipose tissue releases interleukin-6, but not tumor necroses factor-α, in vivo, J. Clin. Endocrinol. Metab. 82 (1997) 4196-4200.
23. J. Zhang, T.D. Pugh, B. Stebler, W.B. Ershler, E.T. Keller, Orchiectomy increases bone marrow interleukin-6 levels in mice, Calcif. Tissue Int. 62 (1998) 219-226.
24. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, E. Vittinghoff, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group, JAMA 280 (1998) 605-613.
25. K.K. Miller, G. Sesmilo, A. Schiller, D. Schoenfeld, S. Burton, A. Klibanski, Androgen deficiency in women with hypopituitarism, J. Clin. Endocrinol. Metab. 86 (2001) 561-567.
26. E.S. Ford, Body mass index, diabetes and C-reactive protein among U.S. adults, Diabetes Care 22 (1999) 1971-1977.
27. P.J. Trainer, W.M. Drake, L. Katznelson, P.U. Freda, V. Herman-Bonert, A.J. van der Lely, E.V. Dimaraki, P.M. Stewart, K.E. Friend, M.L. Vance, G.M. Besser, J.A. Scarlett, M.O. Thorner, C. Parkinson, A. Klibanski, J.S. Powell, A.L. Barkan, M.C. Sheppard, M. Malsonado, D.R. Rose, D.R. Clemmons, G. Johannsson, B.A. Bengtsson, S. Stavrou, D.L. Kleinberg, D.M. Cook, L.S. Phillips, M. Bidlingmaier, C.J. Stasberger, S. Hackett, K. Zib, W.F. Bennett, R.J. Davis, Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant, N. Engl. J. Med. 342 (2000) 1171-1177.
28. G. Sesmilo, W.P. Fairfield, L. Katznelson, K. Pulaski, P.U. Freda, V. Bonert, E. Dimaraki, S. Stavrou, M.L. Vance, D. Hayden, A. Klibanski, Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant, J. Clin. Endocrinol. Metab. 87 (2002) 1692-1699.
29. N. Rifai, P.M. Ridker, Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening, Clin. Chem. 47 (2001) 28-30.
30. P.M. Ridker, N. Rifai, L. Rose, J.E. Buring, N.R. Cook, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N. Engl. J. Med. 347 (2002) 1557-1565.